Abstract
The endocannabinoids anandamide (AEA) and 2-arachidonoylglyerol (2-AG) are endogenous lipid mediators that exert protective roles in pathophysiological conditions, including cardiovascular diseases. In this brief review, we provide a conceptual framework linking endocannabinoid signaling to the control of the cellular and molecular hallmarks, and categorize the key components of endocannabinoid signaling that may serve as targets for novel therapeutics. The emerging picture not only reinforces endocannabinoids as potent regulators of cellular metabolism but also reveals that endocannabinoid signaling is mechanistically more complex and diverse than originally thought.
Keywords:
2-arachidonoylglyerol; Anandamide; Ccardiovascular disease; Insulin resistance.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Amidohydrolases / antagonists & inhibitors
-
Animals
-
Arachidonic Acids / metabolism*
-
Autocrine Communication
-
Cells / metabolism
-
Dronabinol / pharmacology
-
Endocannabinoids / metabolism*
-
Glycerides / metabolism*
-
Humans
-
Mice
-
Molecular Targeted Therapy*
-
Paracrine Communication
-
Polyunsaturated Alkamides / metabolism*
-
Receptor, Cannabinoid, CB1 / agonists
-
Receptor, Cannabinoid, CB1 / antagonists & inhibitors
-
Receptor, Cannabinoid, CB1 / metabolism*
-
Receptor, Cannabinoid, CB2 / agonists
-
Receptor, Cannabinoid, CB2 / antagonists & inhibitors
-
Receptor, Cannabinoid, CB2 / metabolism*
-
Swine
Substances
-
Arachidonic Acids
-
Endocannabinoids
-
Glycerides
-
Polyunsaturated Alkamides
-
Receptor, Cannabinoid, CB1
-
Receptor, Cannabinoid, CB2
-
Dronabinol
-
glyceryl 2-arachidonate
-
Amidohydrolases
-
fatty-acid amide hydrolase
-
anandamide